ZURICH (Reuters) -Swiss contract drug manufacturer Lonza said on Wednesday it has signed an agreement to acquire the Genentech manufacturing facility in Vacaville, California, from drugmaker Roche for $1.2 billion in cash.
Lonza plans to invest around 500 million Swiss francs ($562.30 million) to upgrade the facility and enhance capabilities at the site to accommodate the next generation of mammalian biologics therapies, the company said in a statement.
"The Vacaville site is a highly valuable strategic acquisition that will make capacity immediately available for our customers and unlock future growth for our Biologics division," Jean-Christophe Hyvert, president of Biologics at Lonza, said in the statement.
The transaction is expected to close in the second half of 2024, subject to customary closing conditions.
Basel-based Lonza also said it had updated its 2024-2028 guidance to a sales growth range of 12-15% compound annual growth rate compared with a 11-13% estimate previously.
The Vacaville facility currently has a total bioreactor capacity of around 330,000 liters, making it one of the largest biologics manufacturing sites worldwide by volume, Lonza said.
(Reporting by Miranda Murray Editing by Dave Graham)
Did you find this insightful?
Bad
Just Okay
Amazing